Clinical Trials
17 trialsNCT05176483 2026-05-27
STELLAR-002
Exelixis
Phase 1 Recruiting
NCT03866382 2026-05-26
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04388852 2026-05-20
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02834013 2026-05-13
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07532902 2026-04-16
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04863885 2025-12-17
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03387761 2025-03-05
NABUCCO
The Netherlands Cancer Institute
Phase 1 Completed
NCT03752398 2024-07-05
DUET-3
Xencor, Inc.
Phase 1 Completed
NCT05200988 2024-03-18
Indi-Blade
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT03639714 2023-09-13
A Study of a Personalized Neoantigen Cancer Vaccine
Gritstone bio, Inc.
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT01524991 2022-07-11
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Completed
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown
NCT00362713 2016-09-30
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection
Bristol-Myers Squibb
Phase 1 Completed